Physician profile
Christopher W Hunt
NPI 1235197666
$1,409.19
in general payments reported to CMS, 2019-2025
27 companies · $335 in 2025
The $335 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $133 · 2020: $114 · 2021: $83.39 · 2022: $264 · 2023: $211 · 2024: $268 · 2025: $335.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $814.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $814.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $287.44 | 2019-2025 | Veozah, Myrbetriq |
| Astrazeneca Pharmaceuticals LP | $129.00 | 2025 | Airsupra |
| Novo Nordisk INC | $117.66 | 2019-2023 | Rybelsus, Ozempic |
| Abbott Laboratories | $109.65 | 2022-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Exact Sciences Corporation | $106.59 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Boston Scientific Corporation | $90.82 | 2019-2024 | Watchman Flx |
| Amgen INC. | $83.09 | 2020-2025 | Repatha, Otezla, Otezla |
| Medtronic, INC. | $52.33 | 2024 | Intellis Adaptivestim |
| Abbvie INC. | $50.47 | 2021-2023 | |
| Smith+Nephew, INC. | $43.82 | 2024 | Or3o Dual Mobility, Real Intelligence |
| Pfizer INC. | $36.07 | 2023-2024 | |
| Janssen Pharmaceuticals, INC | $27.35 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.90 | 2019 | |
| Scilex Pharmaceuticals INC. | $24.51 | 2022 | |
| Biosense Webster, INC. | $22.77 | 2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $20.53 | 2025 | |
| Redhill Biopharma INC. | $20.07 | 2020 | |
| Lilly USA, LLC | $19.98 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $18.87 | 2019 | |
| Gilead Sciences, INC. | $18.31 | 2020 | |
| Novartis Pharmaceuticals Corporation | $18.14 | 2022 | |
| Collegium Pharmaceutical, INC. | $16.71 | 2023 | Xtampza |
| Hologic Sales and Service, LLC | $16.69 | 2020 | |
| Amneal Pharmaceuticals LLC | $14.83 | 2020 | |
| Dexcom, INC. | $14.79 | 2024 | Dexcom G6 Transmitter |
| Glaxosmithkline, LLC. | $12.16 | 2022 | |
| Kvk-Tech, INC. | $9.64 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Hunt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.